Chembio Stock Today

CEMI -  USA Stock  

USD 0.63  0.01  1.56%

Market Performance
0 of 100
Odds Of Distress
Over 93
Chembio Diagnostics is trading at 0.63 as of the 24th of May 2022. This is a -1.56 percent down since the beginning of the trading day. The stock's open price was 0.64. Chembio Diagnostics has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Chembio Diagnostics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 24th of April 2022 and ending today, the 24th of May 2022. Click here to learn more.
Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care diagnostic tests that are used to detect or diagnose diseases. Chembio Diagnostics, Inc. was founded in 1985 and is headquartered in Hauppauge, New York. The company has 30.05 M outstanding shares of which 1.77 M shares are currently shorted by private and institutional investors with about 8.21 trading days to cover. More on Chembio Diagnostics
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores

Chembio Diagnostics Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. If you consider yourself one of those investors, make sure you clearly understand your entering position. Chembio Diagnostics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Chembio Diagnostics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Chembio Diagnostics generated a negative expected return over the last 90 days
Chembio Diagnostics has high historical volatility and very poor performance
Chembio Diagnostics has some characteristics of a very speculative penny stock
Chembio Diagnostics has a very high chance of going through financial distress in the upcoming years
The company reported the previous year's revenue of 47.82 M. Net Loss for the year was (33.9 M) with profit before overhead, payroll, taxes, and interest of 12.83 M.
Chembio Diagnostics currently holds about 28.77 M in cash with (30.89 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.96, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Latest headline from www.defenseworld.net: Chembio Diagnostics Coverage Initiated at StockNews.com - Defense World
Chembio Diagnostics Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
Chembio Diagnostics SEC Filings
Chembio Diagnostics SEC Filings Security & Exchange Commission EDGAR Reports
President CEO, DirectorJohn Sperzel  (View All)
Average Analyst Recommendation
Analysts covering Chembio Diagnostics report their recommendations after researching Chembio Diagnostics' financial statements, talking to executives and customers, or listening in on Chembio Diagnostics' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Chembio Diagnostics. The Chembio consensus assessment is calculated by taking the average forecast from all of the analysts covering Chembio Diagnostics.
Piotroski F Score
Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of Chembio Diagnostics based on its profitability, leverage, liquidity, source of funds, and operating efficiency. It is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Chembio Diagnostics financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks.
 5 - HealthyDetails
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares20.2 M24.3 M
Significantly Down
Increasing
Slightly volatile
Weighted Average Shares Diluted20.3 M24.3 M
Fairly Down
Increasing
Slightly volatile
Net Cash Flow from Operations(31.7 M)(30.9 M)
Fairly Down
Decreasing
Slightly volatile
Total Assets58.3 M73.3 M
Significantly Down
Increasing
Slightly volatile
Total Liabilities42.1 M39 M
Significantly Up
Increasing
Slightly volatile
Current Assets59.6 M55.2 M
Significantly Up
Increasing
Slightly volatile
Current Liabilities16.5 M15.3 M
Significantly Up
Increasing
Slightly volatile
Total Debt27.9 M25.9 M
Significantly Up
Increasing
Slightly volatile
Return on Average Assets(0.53)(0.513)
Sufficiently Down
Decreasing
Slightly volatile
Gross Margin0.310.279
Significantly Up
Decreasing
Slightly volatile
Asset Turnover0.840.724
Fairly Up
Decreasing
Slightly volatile
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Chembio Diagnostics' available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Strong SellOvervalued
Financial Strength
Chembio Diagnostics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Chembio Diagnostics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Chembio Diagnostics' financial leverage. It provides some insight into what part of Chembio Diagnostics' total assets is financed by creditors.
Share Download
Share Download
By using current balance sheet information, investors can analyze the liability, assets, and equity on Chembio Diagnostics' books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Chembio Diagnostics deploys its capital and how much of that capital is borrowed.
Liquidity
Chembio Diagnostics cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 25.86 M in liabilities with Debt to Equity (D/E) ratio of 0.75, which is about average as compared to similar companies. Chembio Diagnostics has a current ratio of 3.52, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Chembio Diagnostics until it has trouble settling it off, either with new capital or with free cash flow. So, Chembio Diagnostics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Chembio Diagnostics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Chembio to invest in growth at high rates of return. When we think about Chembio Diagnostics' use of debt, we should always consider it together with cash and equity.

Operating Cash Flow

(31.7 Million)Share
Chembio Diagnostics (CEMI) is traded on NASDAQ Exchange in USA. It is located in 555 Wireless Boulevard and employs 337 people. Chembio Diagnostics is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with current market capitalization of 19.23 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Chembio Diagnostics's market, we take the total number of its shares issued and multiply it by Chembio Diagnostics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Chembio Diagnostics conducts business under Healthcare sector and is part of Diagnostics & Research industry. The entity has 30.05 M outstanding shares of which 1.77 M shares are currently shorted by private and institutional investors with about 8.21 trading days to cover. Chembio Diagnostics currently holds about 28.77 M in cash with (30.89 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.96, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Chembio Diagnostics Probability Of Bankruptcy
Ownership
Chembio Diagnostics holds a total of thirty million fifty thousand outstanding shares. Almost 87.0 percent of Chembio Diagnostics outstanding shares are held by regular investors with 1.31 (percent) owned by insiders and only 11.71 % by other corporate entities. Please note that no matter how much assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.

Ownership Allocation (%)

Check Chembio Ownership Details

Chembio Stock Price Odds Analysis

What are Chembio Diagnostics' target price odds to finish over the current price? In reference to a normal probability distribution, the odds of Chembio Diagnostics jumping above the current price in 90 days from now is about 78.4%. The Chembio Diagnostics probability density function shows the probability of Chembio Diagnostics stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 1.5401 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Chembio Diagnostics will likely underperform. Additionally, the company has a negative alpha, implying that the risk taken by holding this instrument is not justified. Chembio Diagnostics is significantly underperforming DOW.
  Odds Below 0.63HorizonTargetOdds Above 0.63
21.53%90 days
 0.63 
78.40%
Based on a normal probability distribution, the odds of Chembio Diagnostics to move above the current price in 90 days from now is about 78.4 (This Chembio Diagnostics probability density function shows the probability of Chembio Stock to fall within a particular range of prices over 90 days) .

Chembio Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Chembio Diagnostics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Chembio Diagnostics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Chembio Diagnostics' value.
InstituionSecurity TypeTotal SharesValue
Vanguard Group IncCommon Shares1.1 M906 K
Blackrock IncCommon Shares282.5 K231 K
Susquehanna International Group LlpPut Options86.1 K71 K
Group One Trading LpCall Options25.5 K21 K
View Chembio Diagnostics Diagnostics

Chembio Diagnostics Historical Income Statement

Chembio Diagnostics Income Statement is one of the three primary financial statements used for reporting Chembio's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Chembio Diagnostics revenue and expense. Chembio Diagnostics Income Statement primarily focuses on the company's revenues and expenses during a particular period.
Chembio Diagnostics Selling General and Administrative Expense is most likely to increase significantly in the upcoming years. The last year's value of Selling General and Administrative Expense was reported at 24.84 Million View More Fundamentals

Chembio Stock Against Markets

Picking the right benchmark for Chembio Diagnostics stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Chembio Diagnostics stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Chembio Diagnostics is critical whether you are bullish or bearish towards Chembio Diagnostics at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Chembio Diagnostics without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Idea Analyzer Now

   

Idea Analyzer

Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
All  Next Launch Module

Chembio Diagnostics Corporate Directors

Chembio Diagnostics corporate directors refer to members of a Chembio Diagnostics board of directors. The board of directors generally takes responsibility for the Chembio Diagnostics' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Chembio Diagnostics' board members must vote for the resolution. The Chembio Diagnostics board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Barbara DeBuono - Independent DirectorProfile
Peter Kissinger - Independent DirectorProfile
Mary Polan - DirectorProfile
Gary Meller - Independent DirectorProfile

Investing Chembio Diagnostics

You need to understand the risk of investing before taking a position in Chembio Diagnostics. The danger of trading Chembio Diagnostics is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Chembio Diagnostics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Chembio Diagnostics. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Chembio Diagnostics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Continue to Trending Equities. Note that the Chembio Diagnostics information on this page should be used as a complementary analysis to other Chembio Diagnostics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.

Complementary Tools for Chembio Stock analysis

When running Chembio Diagnostics price analysis, check to measure Chembio Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Chembio Diagnostics is operating at the current time. Most of Chembio Diagnostics' value examination focuses on studying past and present price action to predict the probability of Chembio Diagnostics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Chembio Diagnostics' price. Additionally, you may evaluate how the addition of Chembio Diagnostics to your portfolios can decrease your overall portfolio volatility.
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Is Chembio Diagnostics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Chembio Diagnostics. If investors know Chembio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Chembio Diagnostics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Chembio Diagnostics is measured differently than its book value, which is the value of Chembio that is recorded on the company's balance sheet. Investors also form their own opinion of Chembio Diagnostics' value that differs from its market value or its book value, called intrinsic value, which is Chembio Diagnostics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Chembio Diagnostics' market value can be influenced by many factors that don't directly affect Chembio Diagnostics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Chembio Diagnostics' value and its price as these two are different measures arrived at by different means. Investors typically determine Chembio Diagnostics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Chembio Diagnostics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.